Fabry disease in Argentina: an evaluation of patients enrolled in the Fabry Registry

被引:2
|
作者
Politei, J. M. [1 ]
Cabrera, G. [2 ]
Amartino, H. [3 ]
Valdez, R. [4 ]
Masllorens, F. [5 ]
Ripeau, D. [6 ]
Antongiovanni, N. [7 ]
Soliani, A. [8 ]
Luna, P. [9 ]
Cedrolla, M. [10 ]
Fernandez, S. [11 ]
Fainboim, A. [12 ]
机构
[1] Juan Fernandez Hosp, Neurol Serv, RA-1878 Buenos Aires, DF, Argentina
[2] Del Viso Med Ctr, Serv Cardiol, Buenos Aires, DF, Argentina
[3] Austral Hosp, Neuropediatr Serv, Buenos Aires, DF, Argentina
[4] Cent Mil Hosp, Genet Serv, Buenos Aires, DF, Argentina
[5] Posadas Hosp, Genet Serv, Buenos Aires, DF, Argentina
[6] Posadas Hosp, Serv Nephrol, Buenos Aires, DF, Argentina
[7] Pergamino Clin, Serv Nephrol, Buenos Aires, DF, Argentina
[8] Cosme Argerich Hosp, Dermatol Serv, Buenos Aires, DF, Argentina
[9] German Hosp, Dermatol Serv, Buenos Aires, DF, Argentina
[10] High Complex Hosp, Neurol Serv, Formosa, Argentina
[11] Ciperca Srl, Serv Nephrol, Catamarca, Argentina
[12] Ricardo Gutierrez Hosp, Serv Pediat, Buenos Aires, DF, Argentina
关键词
NATURAL-HISTORY DATA; AGALSIDASE BETA TREATMENT; ALPHA-GALACTOSIDASE; RENAL-DISEASE; REPLACEMENT THERAPY; DIALYSIS; FEMALES; LIFE;
D O I
10.1111/ijcp.12081
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: Fabry disease (FD) is an X-linked inborn error of metabolism caused by alpha-galactosidase A deficiency. The Fabry Registry is an ongoing, global observational database that compiles clinical data from patients with FD. Methods: Demographic and baseline clinical characteristics of Fabry Registry patients enrolled in Argentina were analysed and compared with patients enrolled in the rest of the world (ROW). Baseline clinical parameters included chronic kidney disease (CKD) stage, urine protein-to-creatinine ratio and left ventricular posterior wall thickness. Only data from untreated patients were included. Results: As of 1 October 2010, 3752 patients were enrolled in the Registry, 70 patients from Argentina and 3682 from the ROW. Argentinean male subjects were younger than Fabry Registry male subjects enrolled in ROW: mean current age 32.5 years vs. 39.0 years for men (p = 0.0257 by t-test). The current age (mean +/- standard deviation) of female subjects enrolled in Argentina was not significantly different from that of female subjects enrolled in the ROW: 40.1 +/- 17.28 vs. 43.2 +/- 17.95 years respectively (p = 0.2967). Overall, a smaller percentage of patients from Argentina received ERT compared with patients in the ROW (54% vs. 58% respectively). When evaluated by gender, more men and fewer women in Argentina received ERT compared with ROW (85% vs. 79% for men and 27% vs. 38% for women). A larger proportion of patients in ROW had severe CKD (stage 4 or 5) compared with Argentina (9.8% vs. 0%), most likely because of the older age of the ROW population. Conclusions: The enrolment of Argentinean patients into the Fabry Registry has steadily increased, as has the inclusion of female and paediatric patients with FD. The medical community in Argentina should be aware of FD in these populations, as awareness will facilitate prompt diagnosis and initiation of treatment, thus leading to improved outcomes.
引用
收藏
页码:66 / 72
页数:7
相关论文
共 50 条
  • [21] Prevalence of Fabry Disease in Young Patients with Stroke in Argentina
    Reisin, Ricardo C.
    Mazziotti, Julieta
    Leon Cejas, Luciana
    Zinnerman, Alberto
    Bonardo, Pablo
    Fernandez Pardal, Manuel
    Martinez, Alejandra
    Riccio, Patricia
    Ameriso, Sebastian
    Bendersky, Eduardo
    Nofal, Pedro
    Cairola, Patricia
    Jure, Lorena
    Sotelo, Andrea
    Rozenfeld, Paula
    Ceci, Romina
    Casas-Parera, Ignacio
    Sanchez-Luceros, Analia
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2018, 27 (03): : 575 - 582
  • [22] End stage renal disease in patients with Fabry disease: Natural history data from the Fabry registry
    Warnock, David
    Ortiz, Alberto
    Cianciaruso, Bruno
    Cizmarik, Marta
    Germain, Dominique
    Mignani, Renzo
    Oliveira, Joao Paulo
    Villalobos, Jacobo
    Vujkovac, Bojan
    Waldek, Stephen
    Wanner, Christoph
    MOLECULAR GENETICS AND METABOLISM, 2010, 99 (02) : S38 - S38
  • [23] CLINICAL MANIFESTATIONS IN 40 PATIENTS WITH FABRY DISEASE: EXPERIENCE OF THE FABRY STUDY GROUP IN ARGENTINA (GADYTEF)
    Politei, J.
    Valdez, R.
    Masllorens, F.
    Cinque, S.
    Soliani, A.
    Antongiovanni, N.
    Cusumano, A.
    Pedrini, C.
    Fernandez, S.
    Fainboim, A.
    Cabrera, G.
    CLINICAL THERAPEUTICS, 2009, 31 : S30 - S31
  • [24] CLINICAL PROFILE OF BRAZILIAN PATIENTS WITH FABRY DISEASE (FD): DATA FROM BRAZILIAN FABRY REGISTRY
    Martins, A. M.
    Kyosen, S. O.
    Micheletti, C.
    Mendes, C. S. C.
    Gomes, J. G.
    Norato, D.
    Sobral Neto, J.
    Biagini, G.
    Azevedo, D. J.
    Aranda, P. C.
    Sousa, A. F.
    Bastos, R., V
    Chamoles, N. A.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2005, 28 : 163 - 163
  • [25] CHARACTERIZATION OF SYMPTOM ONSET AND CLINICAL EVENTS IN PATIENTS WITH FABRY DISEASE: FINDINGS FROM THE FABRY REGISTRY
    Wanner, C.
    CLINICAL THERAPEUTICS, 2008, 30 : S104 - S104
  • [26] Characterization of symptom onset and clinical events in patients with Fabry disease: Findings from the Fabry Registry
    Eng, Christine
    MOLECULAR GENETICS AND METABOLISM, 2008, 93 (02) : S21 - S21
  • [27] Prevalence of lymphedema among Anderson-Fabry disease patients: A report from the Fabry registry
    Alkhatib, Deya
    Vega, Jesus Avila
    Pour-Ghaz, Issa
    Al-Taweel, Omar
    Khan, Sania
    DeCarr, Kimberly
    Bath, Anandbir
    Rawal, Aranyak
    Wilbanks, David
    Raja, Joel
    Butt, Asra
    Yedlapati, Neeraja
    Hopkin, Robert J.
    Jefferies, John L.
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (04)
  • [28] Fabry stabilization index (FASTEX): Clinical evaluation of disease progression in Fabry disease patients
    Lenders, Malte
    Brand, Eva
    MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) : S97 - S97
  • [29] Nephropathy in Fabry disease: Baseline characteristics of a cohort of 1262 female and male patients in the Fabry registry
    Ortiz, A.
    Oliveira, J. P.
    Waldek, S.
    Warnock, D. G.
    Cianciaruso, B.
    Wanner, C.
    CLINICAL THERAPEUTICS, 2008, 30 : S56 - S56
  • [30] CHARACTERIZATION OF SYMPTOM ONSET AND CLINICAL EVENTS IN PATIENTS WITH FABRY DISEASE: FINDINGS FROM THE FABRY REGISTRY
    Wanner, C.
    CLINICAL THERAPEUTICS, 2009, 31 : S29 - S30